ClinicalTrials.gg
Not yet recruitingNCT06727890MVAUpdated Dec 11, 2024

Compound Danshen Dripping Pill for Diabetic Microvascular Angina

A Phase 4 interventional study of Danshen Dripping Pill and Placebo in Diabetic Microvascular Angina, sponsored by Qilu Hospital of Shandong University. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Qilu Hospital of Shandong University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Microvascular Angina with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Microvascular Angina · China.

Planned enrollment
7th of 10
162 · median 220
Started
2025
with 1 other
Phase 4
7 of 15
5 open now
Registered
12th of 15
by date
Lead sponsor
4 of 15
Qilu Hospital of Shandong University

Among the 15 studies in Microvascular Angina with a site in China, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 4, and was the 12th registered.

Microvascular Angina

111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.

Browse Microvascular Angina studies →

Open to participants now

9 of the 15 studies in Microvascular Angina with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Microvascular Angina studies recruiting now, 17 (63%) set no upper age limit and 3 (11%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Microvascular Angina with a site in China, or all of them as a file.
02

Study summary

To investigate the efficacy and safety of Compound Danshen Dripping Pill in patients with diabetic microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Compound Danshen Dripping Pill on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

03

Conditions studied

  • Diabetic Microvascular Angina

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

History of type 2 diabetes ≧5 years; Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks; Coronary normal or stenosis \<50%; Ischemic depression in ST segment during resting or exercise; Coronary flow reserve (CFR) of the anterior descending coronary artery \< 2.0, or CFR ≧2.0 but acetylcholine activation test is positive; Subjects or their guardians agreed to participate in this study.

Exclusion criteria

Exclusion Criteria:

Previous myocardial infarction or PCI or CABG treatment; Severe arrhythmia; hypertension or hypertension accompanied by left ventricular wall thickness > 12 mm; Familial hypercholesterolemia; Takayasu arteritis, Kawasaki disease or coronary artery malformation; Pregnant or nursing, or having the intention to give birth within one year; Hepatic or renal dysfunction; Allergic to contrast agents or traditional Chinese medicines; Patients who participated in clinical research of other drugs within 3 months before being selected.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Compound Danshen Dripping Pill

    Drug: Danshen Dripping Pill

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugDanshen Dripping Pill

    Danshen Dripping Pill, 10 pills once, three times a day

  • DrugPlacebo

    Placebo, 10 pills once, three times a day

06

What researchers measure

Primary outcomes

  1. Changes of coronary flow reserve measured by three-dimensional echocardiography from baseline to 12 months after follow-up

    Time frame: From baseline to the end of 12-month treatment

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided — It might damage the privacy of patients.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 11, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06727890
Responsible party
Pan-Pan Hao (Dr., Qilu Hospital of Shandong University) — Principal investigator
First posted
Dec 11, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Dec 11, 2024

Study contacts

Panpan Hao, MD, PhD
Contact
panda.how@sdu.edu.cn
86-18560086593

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion